首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   68416篇
  免费   7753篇
  国内免费   4845篇
耳鼻咽喉   675篇
儿科学   761篇
妇产科学   548篇
基础医学   6763篇
口腔科学   1658篇
临床医学   8899篇
内科学   8214篇
皮肤病学   706篇
神经病学   2923篇
特种医学   2665篇
外国民族医学   31篇
外科学   7093篇
综合类   14750篇
现状与发展   21篇
一般理论   6篇
预防医学   5852篇
眼科学   1630篇
药学   7617篇
  119篇
中国医学   5261篇
肿瘤学   4822篇
  2024年   323篇
  2023年   1182篇
  2022年   3196篇
  2021年   4026篇
  2020年   3310篇
  2019年   2394篇
  2018年   2421篇
  2017年   2600篇
  2016年   2302篇
  2015年   3577篇
  2014年   4379篇
  2013年   4323篇
  2012年   6391篇
  2011年   6686篇
  2010年   4948篇
  2009年   4080篇
  2008年   4564篇
  2007年   4047篇
  2006年   3601篇
  2005年   2984篇
  2004年   1952篇
  2003年   1617篇
  2002年   1235篇
  2001年   958篇
  2000年   899篇
  1999年   694篇
  1998年   390篇
  1997年   356篇
  1996年   296篇
  1995年   241篇
  1994年   198篇
  1993年   139篇
  1992年   124篇
  1991年   105篇
  1990年   112篇
  1989年   78篇
  1988年   65篇
  1987年   56篇
  1986年   45篇
  1985年   36篇
  1984年   13篇
  1983年   10篇
  1982年   10篇
  1981年   9篇
  1980年   4篇
  1979年   10篇
  1978年   4篇
  1976年   4篇
  1975年   3篇
  1974年   3篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
BACKGROUND AND PURPOSE: The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-dose rate (LDR) studies, with an estimated loss of local control ranging from 0.3 to 1.6% per day of treatment prolongation. Since the treatment schedule for fractionated high-dose rate intracavitary brachytherapy (HDRICB) is not directly comparable with that for low-dose rate studies, this report aims to evaluate the adverse effect of treatment prolongation specifically for cervical cancer treated with HDRICB. MATERIAL AND METHODS: From September 1992 to December 1997, 257 patients diagnosed with uterine cervical cancer (35 Ib, 26 IIa, 122 IIb, 10 IIIa, 57 IIIb, 7 IVa), who underwent external radiotherapy combined with between two and four courses of HDRICB and a minimum of 3 years of follow-up (median 57 months), were analyzed. Treatment consisted of irradiation of the whole pelvis with 44-45 Gy consisting of 22-25 fractions by 5 weeks, with the dose boosted to 54-58 Gy (with central shielding) for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease. HDRICB was performed using an Ir-192 remote afterloading technique at 1-week intervals. The standard prescribed dose for each course of HDRICB was 7.2 Gy to point A for three insertions (before July 1995), or 6.0 Gy to point A for four insertions (after July 1995). Total prescribed point A doses (external beam radiotherapy+HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while analogous dosage for larger lesions (stage IIb-IVa) ranged from 59 to 75.6 Gy (median, 65.6 Gy). Kaplan-Meier and multivariate analyses were used to test the effect of treatment time on pelvic control rate (PCR) and cause-specific survival (CSS) at 5 years. RESULTS: Median treatment time was 63 days. For all stages of disease, the 5-year CSS and PCR were significantly different comparing treatment times of less than and greater than or equal to 63 days [83% and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. These associations were also significant for stage Ib/IIa [97% and 79% (P=0.01), and 100% and 87% (P=0.02), respectively), but not for stage IIb [75% and 72% (P=0.79), and 93% and 87% (P=0.83), respectively] or stage III [66% and 49% (P=0.2), and 83% and 72% (P=0.21), respectively]. Multivariate analysis identified three prognostic factors for CSS, stage (P<0.001), tumor response to external RT (P=0.001), and overall treatment time (OTT; P=0.006). Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external RT (P=0.001), and OTT (P=0.03). Prolongation of treatment time resulted in a daily decrease in pelvic control rate of 0.67% overall, and 0.43% for stage Ib-IIa, 0.57% for stage IIb, and 0.73% for stage III patients. CONCLUSION: Analysis of the data from the current study demonstrates that the adverse effect of treatment prolongation was observed later in the treatment course for the high-dose rate (HDR) series compared to the LDR analog, however, treatment-time prolongation still negatively influenced the cause-specific survival and pelvic control rate for both dosage groups.  相似文献   
102.
目的 探讨军人花粉症治疗的有效方法。方法 采用提高起始浓度和快速递增浓度 ,上臂外侧皮下注射的方法对 10 6位军人花粉症患者行快速免疫治疗 ,并对每一位患者治疗前后检测血清中总IgE和嗜酸细胞阳离子蛋白 (ECP)。 结果 治疗前后患者总IgE和ECP值有显著性差异。 10 6例患者经 1~ 3年随访复查 ,78例 2个以上发病季节未发作 ,或仅有轻微鼻痒、眼痒 ,18例症状减轻 ,发病时间缩短半月 ,10例症状无明显改善。显效 82例 ,有效 14例 ,无效 10例 ,总有效率为 90 .5 7%。结论 快速免疫治疗能使患者血清总IgE和ECP下降 ,对军人花粉症疗效好。  相似文献   
103.
Objective:To compare the potential incidence of nerve root (ventral and dorsal ramus) injury caused by cervical transarticular screws and Roy-Camille lateral mass screws. Methods:Insertion techniques with Klekamp transarticular screws and Roy-Camille lateral mass screws were respectively performed in this study. Each technique involved four specimens and 40 screws, which were inserted from C3 to C7. And 20-mm-long screws were used to overpenetrate the ventral cortex. The anterolateral aspect of the cervical spine was carefully dissected to allow observation of the screw-ramus relationship. Results : The overall percentage of nerve invasion was significantly lower with Klekamp (45 %) technique than with Roy-Camille (85%) technique (P<0.05). The largest percentage of nerve invasion for Klekamp transarticular screws was found at the dorsal ramus (25%), followed by the ventral ramus (15%) and the bifurcation of the ventral dorsal ramus (5 %). The largest percentage of nerve invasion for Roy-Camille lateral mass screws was found at the ventral ramus (80 %). Conclusion : The potential risk of nerve root invasion is lower with Klekamp transarticular screws than with Roy-Camille lateral mass screws.  相似文献   
104.
乳腺导管瘘的诊断和治疗:附40例报告   总被引:1,自引:0,他引:1  
为探讨乳腺导管瘘的诊断和治疗方法,笔者回顾分析2年间收治的40例乳腺导管瘘患者的临床资料。诊断主要依据病史、体征和病理检查。治疗采用完整切除瘘管和受累乳导管,去除炎性组织,并充分引流的方法,通过肉芽组织生长使乳管瘘痊愈。结果显示,全部病例均治愈,随访其中37例住院治疗的患者2.5年,无1例复发。提示:在治疗上完整切除瘘管和受累乳导管,修复乳头畸形,是防止导管瘘复发的关键。  相似文献   
105.
The human brain cortex is a highly convoluted sheet. Mapping of the cortical surface into a canonical coordinate space is an important tool for the study of the structure and function of the brain. Here, we present a technique based on least-square conformal mapping with spring energy for the mapping of the cortical surface. This method aims to reduce the metric and area distortion while maintaining the conformal map and computation efficiency. We demonstrate through numerical results that this method effectively controls metric and area distortion, and is computational efficient. This technique is particularly useful for fast visualization of the brain cortex.  相似文献   
106.
新基因Tctex5在雄鼠生殖细胞中的表达   总被引:1,自引:0,他引:1  
目的探讨雄鼠生殖细胞中是否有Tctex5基因的表达。方法从三株体外培养的雄鼠生殖细胞CRL-1715、CRL-2053和CRL-2196细胞株中提取总RNA和蛋白,采用RT-PCR和Western blot分别从mRNA和蛋白质水平分析基因产物的表达。结果Tctex5基因在CRL-1715、CRL-2053、CRL-2196三株细胞中都有高表达。结论Tctex5基因作为一个未知功能的基因,在雄鼠生殖细胞中有丰富的表达,可能参与了精子发生的功能调节,作为男性正常生育的。个新的标志物,它可能在精子发生中扮演了一个重要的角色,该基因在雄性生殖细胞中的发现可能会对男性不育的诊断与治疗提供新的途径。  相似文献   
107.
108.
目的:研究中药生精冲剂对大鼠精索静脉曲张的影响及疗效。方法:从80只SD雄性大鼠中随机抽出20只作为假手术组,余60只均建立精索静脉曲张病理模型后随机均分为模型组、生精冲剂组和克罗米芬组。造模后15d生精冲剂组和克罗米酚组分别给予生精冲剂4g/(kg·d)和克罗米芬20mg/(kg·d)灌胃,模型组和假手术组正常喂食。造模后45d放免法测定血清性激素(FSH、LH和T)及观察各组大鼠睾丸组织结构。结果:生精冲剂组大鼠光镜下睾丸组织结构优于模型组和克罗米芬组;血清FSH、LH生精冲剂组显著低于模型组和克罗米芬组(P〈0.05),而克罗米芬组显著高于其他3组。T在生精冲剂组、克罗米芬组和假手术组之间无显著差异,但均显著高于模型组(P〈0.05)。结论:中药生精冲剂对精索静脉曲张引起的睾丸损害有保护及修复作用,且可能优于克罗米芬。  相似文献   
109.
目前全球骨质疏松发病率位于第6位,因此骨质疏松症发病机制一直是重点研究的课题之一,但是骨质疏松的发生、发展、机制至今尚未完全明了.自20世纪20年代发现骨形成和吸收与血液中甲状旁腺素密切相关开始,经过多年探索、研究,甲状旁腺素与骨的形成、吸收的部分机制已经阐明.该文回顾近几年来关于甲状旁腺素与骨质代谢的相关文献,并作一综述.  相似文献   
110.
目的:探讨休克后促炎细胞因子的表达、释放时相及伴随的肠、肝、肺组织病理变化。方法:80只SD大鼠随机均分为失血性休克组和对照组。采用RT-PCR、ELISA方法检测失血性休克后30、60、90min及复苏后30、90min肠、肝、肺组织内TNF-α、IL-6 mRNA表达及血清中TNF-α、IL-6含量;HE和IHC染色检测伴随的组织病理变化。结果:①休克30min时,肠、肝、肺内的促炎细胞因子表达未见升高;60min时肠道先出现TNF-αmRNA表达升高(P〈0.05):而肝脏在90min开始表达升高(P〈0.05),肺脏则在复苏后30min开始表达升高(P〈0.05)。复苏后90min肠、肝、肺的细胞因子表达都继续显著升高(P〈0.01)。②TNF-α 在肠、肝、肺的表达升高最早,其后为IL-6 mRNA。③30min时门静脉和外周血中TNF-α、IM的含量与对照组相比无显著差异,而60min时门静脉血中含量显著升高(P〈0.01)。④休克后肠黏膜坏死脱落;肝组织结构紊乱、肝窦增宽、肝细胞变性坏死;肺脏间质水肿、炎症细胞浸润。结论:失血性休克时细胞因子的释放顺序是肠道、肝脏和肺脏,推测存在“肠-肝-肺”细胞因子释放轴的可能,有待进一步确定。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号